persistent poor glycemic control

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

Longer duration of diabetes (>15 years) was associated with a 41% higher risk of persistently poor glycemic control (HbA1c >9%) compared to shorter duration (RR: 1.41, 95% CI: 1.15-1.72).

Effect: decline; RR: 1.41; CI: 95% CI: 1.15, 1.72

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79

The youngest age group (35-49 years) had persistently worse glycemic control compared to the elderly group (>=65 years), with elderly patients having a 39% lower relative risk of persistent poor contr

Effect: decline; RR: 0.61; CI: 95% CI: 0.47-0.79